Assessing Blueprint Medicines: Insights From 16 Financial Analysts
Assessing Blueprint Medicines: Insights From 16 Financial Analysts
評估blueprint medicines: 16名財務分析師的見解
In the preceding three months, 16 analysts have released ratings for Blueprint Medicines (NASDAQ:BPMC), presenting a wide array of perspectives from bullish to bearish.
在過去的三個月中，有16位分析師發佈了Blueprint Medicines（NASDAQ:BPMC）的評級，呈現出從看好到看淡各種觀點。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
總結他們最近的評估，下表展示了過去30天內不斷變化的情緒，並將其與之前的幾個月進行了比較。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $115.5, a high estimate of $168.00, and a low estimate of $75.00. Marking an increase of 19.69%, the current average surpasses the previous average price target of $96.50.
由分析師分析得出的12個月目標價值反映了市場和投資者對於股價的看法，平均目標價值爲115.5美元，最高預估爲168.00美元，最低預估爲75.00美元。當前平均目標價值比之前的96.50美元提高了19.69%。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析師評級：詳細剖析
A comprehensive examination of how financial experts perceive Blueprint Medicines is...
近期分析師的行動展示出...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。